Conservative Treatment · Evidence-Based Patient Guide
Spine Pain · 34 References

Conservative treatment for spine pain: what works, what doesn’t, and what carries risk.

Every treatment — including non-surgical ones — has a mechanism, a duration of effect, and a risk profile. Understanding all three is the foundation of an informed decision.

Published July 2026 By Dr. Rodrigo Ávila Cervantes Spine Neurosurgeon · FAANS · FCNS 34 references · ~17 min read

Had spine surgery and the pain returned? Send your studies for a second opinion.

Send my studies
The essentials of this article

The majority of patients with spine-related pain — including those with disc herniations, mild stenosis, and degenerative spondylolisthesis — can be managed without surgery, at least for extended periods. The natural history of most degenerative spine conditions favors stability or improvement when structural compression is not severe and neurological function is intact. Understanding when conservative treatment is sufficient, and when it is merely delaying a necessary surgical decision, is the most important skill in spine care management. (Manchikanti, 2014; Hoy, 2010)

The critical distinction

Conservative treatment manages symptoms. It does not repair structural compression. A disc that compresses a nerve root does not move because the patient takes an anti-inflammatory. A stenotic canal does not widen because of physical therapy. When the structural problem requires correction to prevent irreversible damage, delaying surgery is not conservative treatment — it is undertreated disease.

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed medication class for spine pain worldwide. They inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis and thereby reducing pain and inflammation. They are effective for short-term symptom management. They are not disease-modifying — they do not repair discs, reduce herniations, or reverse stenosis. (Kuijpers, 2011; Tulder, 2000)

Duration Benefit Risk
Short-term (≤6 weeks) Documented pain relief; appropriate for acute flares Low with appropriate precautions (PPI co-prescription, avoid in renal/cardiac risk)
Medium-term (6 weeks–3 months) Diminishing symptomatic benefit; tolerance can develop Rising GI risk; monitor renal function and BP
Long-term (>3 months) No additional structural benefit; symptom management only Significant: GI bleeding, cardiovascular events (MI, stroke), chronic kidney disease, hypertension

The practical answer: NSAIDs are a reasonable tool for managing acute painful flares — the 5 days when the pain from an acute disc herniation is at its worst, or the days after a long-standing stenosis suddenly worsens. They are not a chronic solution. A patient who has been taking NSAIDs daily for 6 months for spine pain has a poorly managed condition that requires reassessment, not dose escalation.

Muscle relaxants are a heterogeneous drug class. The centrally acting agents (cyclobenzaprine, baclofen, methocarbamol, carisoprodol) work primarily through CNS depression rather than direct action on muscle tissue. Their effect on acute muscle spasm is real but short-lived. Their risk profile for prolonged use is significant. (Kuijpers, 2011)

Appropriate use
Short-term (7–14 days) for acute muscle spasm accompanying an acute disc herniation or vertebral fracture. Taken at night to minimize sedation and functional impairment during the day.
Problematic use
Chronic use (>4 weeks): tolerance, physical dependence, withdrawal syndrome on discontinuation, cognitive impairment, and falls risk in older adults. Carisoprodol in particular has high abuse potential.

This question requires separating three distinct types of injections that are often conflated in patient conversations:

Types of spinal injections — what they target
  • 1Epidural steroid injections (ESI) — interlaminar, transforaminal, or caudal routes. Deliver corticosteroid into the epidural space to reduce nerve root inflammation. Evidence: short-term benefit (4–6 weeks) for radiculopathy from disc herniation is documented. Evidence for stenosis is weaker. (Manchikanti, 2016; Fang, 2022)
  • 2Facet joint injections — intra-articular injection of steroid into the zygapophyseal joint. Indicated when facet joint arthropathy is the pain generator. Evidence: moderate benefit for facetogenic pain; positive response predicts favorable outcome of medial branch radiofrequency ablation. (Kim BR, 2020; Boswell, 2007)
  • 3Medial branch blocks / radiofrequency ablation — blocks or ablates the medial branch nerve that innervates the facet joint. When facet pain is confirmed by two diagnostic blocks, radiofrequency ablation can provide 6–18 months of relief. Evidence quality: moderate. (Manchikanti, 2012; Boswell, 2007)

The critical point that all three have in common: none of them modify the structural cause of compression. A disc herniation that compresses a nerve does not retract because of an epidural steroid injection. The injection reduces the inflammatory component of nerve root irritation — which can be significant in acute radiculopathy — but the structural compression remains. In a patient who was going to improve spontaneously anyway (which the majority of disc herniations do), the injection accelerates the symptomatic course. In a patient with fixed structural compression, it buys time — with a cost.

Injection-based spine treatments are widely performed, widely underestimated in terms of risk, and in many centers inadequately monitored for complications. A 2022 prospective study by Voelker et al. systematically documented complications in a unicentric cohort — providing some of the most rigorous real-world data on the subject. The complications fall into three categories by severity. (Voelker, 2022)

Minor / Common
Vasovagal reaction (most frequent) · Transient flushing · Temporary pain exacerbation (post-injection flare) · Hyperglycemia in diabetic patients · Headache from dural puncture (usually self-limiting)
Serious / Rare
Epidural abscess · Meningitis · Septic arthritis (facet injections) · Epidural hematoma (risk with anticoagulation) · Subdural injection · Spinal cord infarction (particulate steroid in transforaminal — catastrophic, rare) · Neurological injury
Cumulative steroid risks with repeated injections

Repeated epidural steroid injections can measurably reduce bone mineral density in postmenopausal women — a clinically significant risk in a population already prone to osteoporosis (Al-Shoha, 2012; Kim YU, 2016). Adrenal suppression from repeated glucocorticoid exposure is documented, though typically transient. The FDA issued a warning in 2014 about the risk of rare but severe neurological events following transforaminal cervical and lumbar epidural steroid injections (Manchikanti, 2014). Each injection carries its own risk. Multiple injections carry cumulative risk. There is no universally agreed safe maximum number.

The instinct to rest completely during severe pain is understandable. The evidence against prolonged bed rest is now one of the most consistent findings in the spine literature. The 2017 Cochrane overview of reviews on physical activity and exercise for chronic pain in adults (Geneen et al., covering dozens of systematic reviews) found that physical activity is consistently superior to rest for chronic pain, and that prolonged immobility leads to measurable physical and psychological deterioration. (Geneen, 2017)

1–2
days of relative rest: reasonable in acute severe disc herniation before beginning gentle mobilization
>7
days of bed rest: consistently associated with worse outcomes — more disability, slower recovery, greater psychological impact
0
benefit of prolonged bed rest over gradual mobilization in any randomized trial of acute low back pain (Hoy, 2010)

The exception: cauda equina syndrome and acute cord compression require complete rest until surgical decompression. These are true emergencies where movement can worsen the neurological deficit. In every other scenario, the goal is graduated, progressive mobilization as soon as pain permits.

Back braces are one of the most recommended and least evidence-supported interventions in spine care. Their role is context-dependent. (Bell, 1988; Spratt, 1993; Prateepavanich, 2001)

Evidence-supported uses
Acute vertebral fractures (limiting painful flexion while awaiting healing or vertebroplasty) · Short-term (2–6 weeks) activity modification in acute spondylolisthesis flares · Proprioceptive feedback in the early postoperative period
Problematic uses
Long-term daily use: paraspinal muscle atrophy from disuse · Psychological dependence · Does not address the structural cause · Does not prevent slip progression in spondylolisthesis · Long-term use worsens the condition it attempts to treat

This category encompasses treatments with widely varying evidence bases, cultural adoption, and risk profiles. The honest answer requires separating what the evidence shows for specific diagnoses, rather than giving a blanket endorsement or rejection.

Therapy For non-specific LBP For radiculopathy / structural pathology Contraindications
Acupuncture Some evidence for short-term pain reduction vs. sham No evidence for radiculopathy or structural stenosis Bleeding disorders, anticoagulation, infection at needle sites
Spinal manipulation / chiropractic Moderate evidence for acute non-specific LBP (Mierau, 1987) Contraindicated or no benefit in stenosis, Grade II+ spondylolisthesis, radiculopathy with deficit Osteoporosis, instability, myelopathy, anticoagulation
Massage therapy Some evidence for short-term relief in non-specific LBP No structural benefit; adjunct only for muscle tension Active infection, fracture, tumor, anticoagulation
TENS / heat / ultrasound Minimal to no evidence beyond placebo for chronic LBP No benefit for structural pathology Metallic implants (TENS, ultrasound)

The most important clinical point: spinal manipulation carries documented risks in structural spine pathology. High-velocity manipulation applied to a segment with active disc herniation and radiculopathy, severe stenosis, spondylolisthesis with instability, or osteoporosis can worsen the condition and has caused permanent neurological injury in documented cases. A positive response to manipulation in non-specific LBP does not generalize to structural pathology. (Mierau, 1987; Boswell, 2007)

Exercise is the single most evidence-supported non-pharmacological intervention for chronic spine pain. The distinction that matters clinically is between pain that signals damage and pain that is the expected response to exercise in a sensitized nervous system — commonly called “good pain” versus “bad pain.” Knowing which is which requires clinical judgment that cannot be reduced to a simple rule. (Geneen, 2017; O’Sullivan, 1997)

Signs that warrant stopping exercise immediately
  • New or worsening weakness in the leg or foot during or after exercise
  • New numbness in the perineal or genital area, or difficulty urinating — possible cauda equina emergency
  • Pain that radiates significantly into the leg during or after exercise, when this is a new symptom or a clear worsening of a known pattern
  • Difficulty walking or balancing that is new after exercise

Exercise type matters for specific diagnoses. Core stabilization exercises have the strongest evidence for spondylolisthesis — they reduce shear forces at the unstable segment. Extension-based exercises (McKenzie protocol) may worsen stenosis and spondylolisthesis by reducing the already-narrowed canal diameter. Flexion-based exercises and cycling are generally well-tolerated in stenosis because they open the canal. Walking in the pool or cycling are often the first aerobic modalities for patients with significant claudication. (O’Sullivan, 1997; Kalichman, 2008)

The relationship between psychological factors and chronic spine pain is not a matter of the pain “being in the patient’s head” — a reductive and harmful framing. It is a matter of understanding how the nervous system modulates the experience and perception of pain signals that are structurally real. Psychosocial factors — what clinicians call “yellow flags” — are among the strongest predictors of who transitions from acute to chronic pain. (Manchikanti, 2008; Hall, 2019)

Key psychosocial predictors of chronic pain transition (yellow flags)
  • 1Catastrophizing — believing the pain is worse than it is, that it signals irreversible damage, or that nothing will help; one of the single strongest predictors of chronicity
  • 2Fear-avoidance — avoiding movement because of fear of pain, leading to progressive deconditioning
  • 3Depression and anxiety — both are causes and consequences of chronic pain; addressing them is part of treatment
  • 4Work-related factors — job dissatisfaction, conflict with supervisor, litigation; predict delayed recovery independent of the physical findings

Cognitive behavioral therapy (CBT) has the highest level of evidence for chronic low back pain among psychological interventions — not as a replacement for structural treatment when it is indicated, but as an adjunct that improves outcomes significantly. A structural problem is not made worse by addressing the psychological component; it is made easier to manage. The biopsychosocial model of pain is not a concession to weakness; it is the most accurate description of how pain works.

Chronic pain is defined by duration: symptoms that persist beyond 12 weeks. Approximately 20% of patients who experience an acute episode of low back pain transition to chronic pain. Understanding why that 20% is different from the 80% who recover is one of the central questions in spine pain research. (Manchikanti, 2014; Simotas, 2000)

The transition from acute to chronic is not simply a matter of time passing. It involves neuroplastic changes in the spinal cord and brain that amplify pain processing — central sensitization. The persistent, unresolved structural stimulus (a herniation that does not reabsorb, a canal that does not decompress) drives this sensitization. But the psychological and behavioral factors described in the previous section independently accelerate the transition, regardless of the structural substrate. This is why two patients with identical MRI findings can have completely different pain experiences and clinical trajectories.

Conservative treatment is not passive waiting. It is an active strategy with a time limit, a risk profile, and a clear goal.

Every treatment in this article — NSAIDs, muscle relaxants, epidural injections, braces, acupuncture, exercise, CBT — has a mechanism of action, a duration window during which it is appropriate, and a risk profile that is rarely communicated explicitly to patients. The patient who has been taking daily NSAIDs for 8 months while being told to “keep trying conservative treatment” is not receiving conservative treatment. They are receiving undertreated structural disease with chronic NSAID exposure.

The risks of conservative treatment are real, documented, and underemphasized. Repeated epidural steroid injections reduce bone mineral density. Spinal manipulation in the wrong patient causes neurological injury. Prolonged bed rest causes deconditioning that outlasts the episode that triggered it. Long-term muscle relaxant use produces dependence. Long-term brace use produces atrophy of the muscles the brace was supposed to protect. These are not theoretical risks — they are published, prospectively documented outcomes.

The correct framework for conservative treatment is not “try everything before surgery.” It is: define the structural problem precisely, match the treatment to that specific problem, set a time limit for each intervention, monitor for response, and escalate to surgery when conservative treatment has failed or when neurological function is at risk. A spine specialist who cannot explain clearly why a specific conservative treatment is being proposed for your specific diagnosis, what the expected duration of benefit is, and what the risks of that treatment are, has not yet completed their assessment.

Dr. Rodrigo Ávila Cervantes
Spine Neurosurgeon · FAANS · FCNS · CICOVE Director · Hospital Ángeles del Pedregal
CICOVE · Hospital Ángeles del Pedregal · Mexico City

Have you been in conservative treatment for months without improvement? Send Dr. Ávila your studies.

Personal response within 48–72 hours. No charge for the case review.

References

34 peer-reviewed references · 1987–2025 · Including Cochrane reviews, NEJM, Lancet, Pain Physician, and European Spine Journal

  1. Voelker A, Pirlich M, Heyde CE. Complications of injections in conservative treatment of degenerative spine disease: a prospective unicentric study. BMC Musculoskelet Disord. 2022;23:1002. PMID: 36419001
  2. Manchikanti L et al. A prospective evaluation of complications of 10,000 fluoroscopically directed epidural injections. Pain Physician. 2012;15:131-140.
  3. Manchikanti L et al. Epidural injections for lumbar radiculopathy and spinal stenosis: a comparative systematic review and meta-analysis. Pain Physician. 2016;19:E365-410.
  4. Feeley IH et al. Particulate and non-particulate steroids in spinal epidurals: a systematic review and meta-analysis. Eur Spine J. 2017;26:336-344.
  5. Fang Z et al. Comparison of clinical efficacy of epidural injection with or without steroids in the treatment of degenerative disc disease: meta-analysis. Pain Physician. 2022;25:145-160.
  6. Chang A, Ng AT. Complications associated with lumbar transforaminal epidural steroid injections. Curr Pain Headache Rep. 2020;24:67.
  7. Kim BR et al. Intra-articular facet joint steroid injection-related adverse events encountered during 11,980 procedures. Eur Radiol. 2020;30:1507-1516.
  8. Al-Shoha A et al. Effect of epidural steroid injection on bone mineral density in postmenopausal women. Spine. 2012;37:E1567-71.
  9. Manchikanti L et al. Complications of fluoroscopically directed facet joint nerve blocks: a prospective evaluation of 7,500 episodes with 43,000 nerve blocks. Pain Physician. 2012;15:E143-E150.
  10. Derby R et al. Size and aggregation of corticosteroids used for epidural injections. Pain Med. 2008;9:227-234.
  11. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723.
  12. Schmidt CM, Haage P, Stückle CA. Volumetric measurement of herniated disc material as a predictor of outcome in periradicular therapy. Eur Spine J. 2025;34(10):4404-4414. PMID: 40921849
  13. Tulder MW et al. Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the Cochrane collaboration. Spine. 2000;25:2501-2513.
  14. Kuijpers T et al. A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. Eur Spine J. 2011;20:40-50.
  15. Shimba A, Ikuta K. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol. 2020;42:669-680.
  16. Manchikanti L. Role of neuraxial steroids in interventional pain management. Pain Physician. 2002;5:182-199.
  17. Manchikanti L et al. Epidemiology of low back pain in adults. Neuromodulation: J Int Neuromodulation Soc. 2014;17(Suppl 2):3-10.
  18. Manchikanti L, Cash KA, Pampati V et al. Influence of psychological variables on the diagnosis of facet joint involvement in chronic spinal pain. Pain Physician. 2008;11:145-160.
  19. Geneen LJ et al. Physical activity and exercise for chronic pain in adults: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;4:CD011279.
  20. Hoy D et al. The epidemiology of low back pain. Best Pract Res Clin Rheumatol. 2010;24:769-781.
  21. O'Sullivan PB et al. Evaluation of specific stabilizing exercise in the treatment of chronic low back pain with radiologic diagnosis of spondylolysis or spondylolisthesis. Spine. 1997;22:2959-2967.
  22. Bell DF, Ehrlich MG, Zaleske DJ. Brace treatment for symptomatic spondylolisthesis. Clin Orthop Relat Res. 1988;236:192-198.
  23. Spratt KF et al. Efficacy of flexion and extension treatments incorporating braces for low-back pain patients with retrodisplacement, spondylolisthesis, or normal sagittal translation. Spine. 1993;18:1839-1849.
  24. Prateepavanich P et al. The effectiveness of lumbosacral corset in symptomatic degenerative lumbar spinal stenosis. J Med Assoc Thai. 2001;84:572-576.
  25. Mierau D et al. A comparison of the effectiveness of spinal manipulative therapy for low back pain in patients with and without spondylolisthesis. J Manipulative Physiol Ther. 1987;10:49-55.
  26. Boswell MV et al. A systematic review of therapeutic facet joint interventions in chronic spinal pain. Pain Physician. 2007;10:229-253.
  27. Boswell MV et al. Therapeutic facet joint interventions in chronic spinal pain: a systematic review of effectiveness and complications. Pain Physician. 2005;8:101-114.
  28. Jacobs WC et al. Surgery versus conservative management of sciatica due to a lumbar herniated disc: a systematic review. Eur Spine J. 2011;20:513-522.
  29. Manchikanti L et al. Transforaminal epidural injections in chronic lumbar disc herniation: a randomized, double-blind, active-control trial. Pain Physician. 2014;17:E489-501.
  30. Manchikanti L et al. Epidural steroid warning controversy still dogging FDA. Pain Physician. 2014;17:E451-E474.
  31. Hall JA et al. Systematic Review of Decision Analytic Modelling in Economic Evaluations of Low Back Pain and Sciatica. Appl Health Econ Health Policy. 2019;17:467-491.
  32. Kim YU et al. Effect of epidural steroid injection on bone mineral density in postmenopausal women according to antiosteoporotic medication use. Pain Physician. 2016;19:389-396.
  33. Simotas AC et al. Nonoperative treatment for lumbar spinal stenosis: clinical and outcome results and a 3-year survivorship analysis. Spine. 2000;25:197-203.
  34. Kalichman L, Hunter DJ. Diagnosis and conservative management of degenerative lumbar spondylolisthesis. Eur Spine J. 2008;17:327-335. PMID: 18026865
Second opinionSend studies